- Home
- ATEX vs BCYC Comparison
ATEX vs BCYC Comparison
Compare ATEX & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATEX
- BCYC
- Stock Information
- Founded
- ATEX 1997
- BCYC 2009
- Country
- ATEX United States
- BCYC United Kingdom
- Employees
- ATEX N/A
- BCYC 305
- Industry
- ATEX Telecommunications Equipment
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- ATEX Telecommunications
- BCYC Health Care
- Exchange
- ATEX Nasdaq
- BCYC Nasdaq
- Market Cap
- ATEX 381.9M
- BCYC 449.5M
- IPO Year
- ATEX N/A
- BCYC 2019
- Fundamental
- Price
- ATEX $22.58
- BCYC $6.52
- Analyst Decision
- ATEX Buy
- BCYC Buy
- Analyst Count
- ATEX 2
- BCYC 11
- Target Price
- ATEX $58.50
- BCYC $20.73
- AVG Volume (30 Days)
- ATEX 220.0K
- BCYC 349.5K
- Earning Date
- ATEX 11-12-2025
- BCYC 10-30-2025
- Dividend Yield
- ATEX N/A
- BCYC N/A
- EPS Growth
- ATEX N/A
- BCYC N/A
- EPS
- ATEX 5.13
- BCYC N/A
- Revenue
- ATEX $5,925,000.00
- BCYC $28,339,000.00
- Revenue This Year
- ATEX N/A
- BCYC N/A
- Revenue Next Year
- ATEX $5.18
- BCYC N/A
- P/E Ratio
- ATEX $4.42
- BCYC N/A
- Revenue Growth
- ATEX 5.67
- BCYC N/A
- 52 Week Low
- ATEX $17.58
- BCYC $6.10
- 52 Week High
- ATEX $42.91
- BCYC $23.51
- Technical
- Relative Strength Index (RSI)
- ATEX 66.42
- BCYC 38.60
- Support Level
- ATEX $17.82
- BCYC $6.19
- Resistance Level
- ATEX $18.55
- BCYC $6.89
- Average True Range (ATR)
- ATEX 0.98
- BCYC 0.52
- MACD
- ATEX 0.34
- BCYC -0.11
- Stochastic Oscillator
- ATEX 96.96
- BCYC 13.26
About ATEX Anterix Inc.
Anterix Inc is a United States-based company engaged in delivering broadband needed to modernize infrastructure for energy, transportation, logistics, and other industries. The company offers Private LTE for utilities which help to automate processes, monitor environmental conditions, enable artificial intelligence, and drive productivity.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.